Conditions: Hypercholesterolemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 203
Healthy volunteers: no

Brief summary:
This is an efficacy and safety study of Vytorin (ezetimibe (+) simvastatin) compared to atorvastatin (ezetimibe/simvastatin) at week 6 in primary hypercholesterolemia patients in Korea. The primary hypothesis being tested is that daily administration of Vytorin will result in a greater reduction of low density lipoprotein cholesterol (LDL-C) concentration from baseline after 6 weeks treatment compared to atorvastatin.

Detailed description:

Arms:
arm 1: Ezetimibe 10 mg/Simvastatin 20 mg arm 2: Atorvastatin 10 mg

Interventions: intervention 1: ezetimibe (+) simvastatin intervention 2: atorvastatin
Intervention descriptions: intervention 1: simvastatin/ezetimibe 10/20 mg intervention 2: atorvastatin 10 mg

Protocol document: